SecBot SecBot
8-K ·Filed Apr 13, 2026

DRIO

DarioHealth Corp.
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001104659-26-042362
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral

Monitor for potential strategic partnerships or commercial scaling initiatives given Palumbo's extensive network in healthcare systems, payers, and digital health. No immediate financial impact expected.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
DRIO ▼ -1.63% at T+60d
NEUTRAL call -1.63% · α vs SPY -10.56% · entry $7.34 → $7.22
Entry = T+0 close
Apr 13, 2026
via day close
T+1d
+3.00%
call +3.00% · α +1.79%
$7.56
settled 7mo ago
T+5d
+1.63%
call +1.63% · α -1.66%
$7.46
settled 6mo ago
T+20d
+8.72%
call +8.72% · α +0.99%
$7.98
settled 6mo ago
T+60d
-1.63%
call -1.63% · α -10.56%
$7.22
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

DarioHealth appointed John R. Palumbo to its Board of Directors, effective April 10, 2026. Palumbo brings over 40 years of healthcare leadership experience, including roles at AmerisourceBergen and Allscripts, and currently serves on multiple healthcare boards.

Key Facts

  • John R. Palumbo was appointed to DarioHealth's Board of Directors effective April 10, 2026
  • Palumbo has over 40 years of healthcare operating experience, including senior roles at AmerisourceBergen and Allscripts
  • He currently serves on the boards of PM Pediatrics, Lucid Diagnostics (LUCD), ivWatch, QLess, and chairs Brado Ai's advisory board
  • Palumbo will receive the same fees as other non-executive directors
  • No arrangement or understanding exists between Palumbo and any other person regarding his appointment

Financial Impact

Minimal immediate financial impact. Director compensation is standard for non-executive members.

operating expensesgovernance

Risk Factors

  • Potential for increased director compensation expenses over time
  • Risk of board overextension given Palumbo's multiple board commitments

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-042362
Document: tm2611605d1_ex99-1.htm0001104659-26-042362
Document: 0001104659-26-042362-index-headers.html0001104659-26-042362
Document: 0001104659-26-042362-index.html0001104659-26-042362
Document: 0001104659-26-042362.txt0001104659-26-042362
4 reports for DRIO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DRIO — sortable, filterable
TypeNow
Jul 22, 2026
13w ago
424B5
BEARISH ★ 6/10
$7.47 $5.13▲ +31.33%▲ +35.88%$3.23 (+56.76%)
Apr 13, 2026
28w ago
3
NEUTRAL ★ 2/10
$7.56 $7.00▼ −7.41%▼ −15.93%$3.23 (−57.28%)
Apr 13, 2026
28w ago
8-K
NEUTRAL ★ 3/10
$7.34 $7.22▼ −1.63%▼ −10.56%$3.23 (−55.99%)
Mar 30, 2026
30w ago
EFFECT
NEUTRAL ★ 3/10
$8.19 $6.15▼ −24.91%▼ −41.40%$3.23 (−60.56%)
Showing 4 of 4

US Market Status

Market Open — Closes in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026